HK1045714B - 重組血小板膠原受體糖蛋白vi及其藥用 - Google Patents

重組血小板膠原受體糖蛋白vi及其藥用

Info

Publication number
HK1045714B
HK1045714B HK02107061.7A HK02107061A HK1045714B HK 1045714 B HK1045714 B HK 1045714B HK 02107061 A HK02107061 A HK 02107061A HK 1045714 B HK1045714 B HK 1045714B
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical use
collagen receptor
recombinant platelet
receptor glycoprotein
platelet collagen
Prior art date
Application number
HK02107061.7A
Other languages
English (en)
Other versions
HK1045714A1 (en
Inventor
K‧J‧克萊米特森
Original Assignee
薩諾費-阿文蒂斯德國有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1045714(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 薩諾費-阿文蒂斯德國有限公司 filed Critical 薩諾費-阿文蒂斯德國有限公司
Publication of HK1045714A1 publication Critical patent/HK1045714A1/xx
Publication of HK1045714B publication Critical patent/HK1045714B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/018—Platelets
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
HK02107061.7A 1999-05-07 2002-09-26 重組血小板膠原受體糖蛋白vi及其藥用 HK1045714B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99109094 1999-05-07
PCT/EP2000/003683 WO2000068377A1 (en) 1999-05-07 2000-04-25 Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use

Publications (2)

Publication Number Publication Date
HK1045714A1 HK1045714A1 (en) 2002-12-06
HK1045714B true HK1045714B (zh) 2006-09-22

Family

ID=8238132

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02107061.7A HK1045714B (zh) 1999-05-07 2002-09-26 重組血小板膠原受體糖蛋白vi及其藥用

Country Status (26)

Country Link
US (5) US7928066B1 (zh)
EP (3) EP1942186B1 (zh)
JP (2) JP5480457B2 (zh)
KR (1) KR100703592B1 (zh)
CN (1) CN1253569C (zh)
AR (1) AR023848A1 (zh)
AT (1) ATE393223T1 (zh)
AU (1) AU775952B2 (zh)
BR (1) BRPI0010325B1 (zh)
CA (1) CA2372515C (zh)
CY (2) CY1108190T1 (zh)
CZ (1) CZ302693B6 (zh)
DE (1) DE60038675T2 (zh)
DK (2) DK1177289T3 (zh)
ES (2) ES2534652T3 (zh)
HK (1) HK1045714B (zh)
HU (1) HUP0201049A2 (zh)
MX (1) MXPA01011274A (zh)
NO (1) NO333408B1 (zh)
PL (1) PL204449B1 (zh)
PT (2) PT2341141E (zh)
RU (1) RU2287580C2 (zh)
SI (1) SI1177289T1 (zh)
SK (1) SK15762001A3 (zh)
WO (1) WO2000068377A1 (zh)
ZA (1) ZA200110071B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK15762001A3 (sk) 1999-05-07 2002-04-04 Merck Patent Gmbh Rekombinantný doštičkový kolagénový receptor glykoproteínu VI a jeho farmaceutické použitie
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
EP1406929A2 (en) * 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusion proteins
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
DE102004017295A1 (de) * 2004-04-05 2005-11-03 Zlb Behring Gmbh Verbindungen, welche die Entfernung von Rezeptoren von Zelllmembranen bewirken oder verhindern, und Verfahren zu ihrem Nachweis
CN1964990B (zh) 2004-04-29 2012-12-12 大冢制药株式会社 糖蛋白ⅵ特异的抗体以及生产这些抗体的方法
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
RU2010121878A (ru) * 2007-10-31 2011-12-10 Оцука Фармасьютикал Ко., Лтд. (Jp) Применения ингибитора гликопротеина vi (gpvi)
EP2694709B1 (en) 2011-04-08 2016-09-14 Prognosys Biosciences, Inc. Peptide constructs and assay systems
EP3184544A1 (en) * 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT662088E (pt) 1993-07-01 2002-06-28 Merck Patent Gmbh Inibidor da agregacao de plaquetas estimulada por colagenio
AU701576B2 (en) * 1993-10-22 1999-02-04 Trigen Limited Platelet-derived growth factor analogues
AU5927398A (en) * 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Fc receptors and polypeptides
CA2250291A1 (en) * 1997-01-29 1998-07-30 Toray Industries Inc. Chimeric proteins, their heterodimer complexes, and platelet substitutes
SK15762001A3 (sk) 1999-05-07 2002-04-04 Merck Patent Gmbh Rekombinantný doštičkový kolagénový receptor glykoproteínu VI a jeho farmaceutické použitie
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1406929A2 (en) 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusion proteins
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4

Also Published As

Publication number Publication date
NO333408B1 (no) 2013-05-27
AU4555500A (en) 2000-11-21
CZ20013989A3 (cs) 2002-02-13
CN1350583A (zh) 2002-05-22
JP5554696B2 (ja) 2014-07-23
KR20010112951A (ko) 2001-12-22
HK1045714A1 (en) 2002-12-06
EP1177289B1 (en) 2008-04-23
CY1116336T1 (el) 2017-02-08
JP2011097948A (ja) 2011-05-19
CA2372515C (en) 2015-12-01
PL204449B1 (pl) 2010-01-29
DE60038675D1 (de) 2008-06-05
AR023848A1 (es) 2002-09-04
EP1942186A2 (en) 2008-07-09
DK1177289T3 (da) 2008-08-11
CZ302693B6 (cs) 2011-09-07
EP2341141B1 (en) 2015-01-14
PT1177289E (pt) 2008-06-30
US20160207976A1 (en) 2016-07-21
DK2341141T3 (en) 2015-04-20
KR100703592B1 (ko) 2007-04-05
EP1942186B1 (en) 2017-04-12
RU2287580C2 (ru) 2006-11-20
EP1177289A1 (en) 2002-02-06
HUP0201049A2 (hu) 2002-07-29
EP1942186A3 (en) 2008-10-08
NO20015420D0 (no) 2001-11-06
NO20015420L (no) 2002-01-03
ATE393223T1 (de) 2008-05-15
US7928066B1 (en) 2011-04-19
JP5480457B2 (ja) 2014-04-23
US20070172893A1 (en) 2007-07-26
DE60038675T2 (de) 2009-07-02
AU775952B2 (en) 2004-08-19
JP2003515313A (ja) 2003-05-07
MXPA01011274A (es) 2002-05-06
EP2341141A3 (en) 2012-03-28
SK15762001A3 (sk) 2002-04-04
WO2000068377A1 (en) 2000-11-16
US8198030B2 (en) 2012-06-12
EP2341141A2 (en) 2011-07-06
BRPI0010325B1 (pt) 2016-01-19
CY1108190T1 (el) 2014-02-12
SI1177289T1 (sl) 2008-08-31
US20070172480A1 (en) 2007-07-26
CN1253569C (zh) 2006-04-26
PT2341141E (pt) 2015-04-30
US20110237655A1 (en) 2011-09-29
US8278430B2 (en) 2012-10-02
PL351437A1 (en) 2003-04-22
ZA200110071B (en) 2003-03-06
ES2534652T3 (es) 2015-04-27
CA2372515A1 (en) 2000-11-16
ES2304347T3 (es) 2008-10-16
BR0010325A (pt) 2002-02-26

Similar Documents

Publication Publication Date Title
PL351437A1 (en) Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use
PT1163271E (pt) Anticorpos il-18 recombinantes e a sua utilização
IL181468A (en) E2 subunit vaccine comprising recombinant pestivirus e2 protein
HUP9801433A2 (hu) IIb/IIIa Glikoprotein antagonisták, ezek előállítása és alkalmazása, valamint ezeket tartalmazó gyógyászati készítmények
HUP0200418A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
HUP0100149A3 (en) Antipicornaviral peptide derivatives pharmaceutical compositions comprising thereof and their use
IL122641A0 (en) Vitronectin receptor antagonists their preparation and their use
IL130229A0 (en) Novel human beta2 integrin alpha subunit
IL135797A (en) Thrombin receptor antagonists and pharmaceutical compositions comprising them
IL133686A0 (en) Glycoprotein hormone analogs, their preparation and use
IL122643A0 (en) Vitronectin receptor antagonists their preparation and their use
EP1207198A4 (en) G-PROTEIN COUPLED RECEPTOR PROTEIN AND ITS DNA
CZ2000522A3 (cs) Farmaceutický prostředek na bázi piperidinalkanolového antihistaminika a použití
HUP0204113A3 (en) Novel integrin receptor antagonists, pharmaceutical compositions containing them and their use
IL133318A0 (en) Proteoglycans and pharmaceutical compositions comprising them
EP1239039A4 (en) NEW POLYPEPTIDE AND ENCODING DNA
EP1151006A4 (en) HUMAN G PROTEIN TORQUE RECEPTOR
IL131266A0 (en) Peptides and pharmaceutical compositions comprising same
EP1207201A4 (en) PROTEIN G-COUPLED RECEPTOR AND CORRESPONDING DNA
IL131719A0 (en) Iren protein its preparation and use
EP1241257A4 (en) TACHYKININ-SIMILAR POLYPEPTIDES AND ITS APPLICATION
GB9917165D0 (en) Polypeptides polynuclcotides and uses thereof
GB9801621D0 (en) Recombinant birA protein
EP0928194A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTERING INTEGRIN RECEPTOR ANTAGONISTS
AU2002367139A8 (en) Human netrin receptor and uses thereof

Legal Events

Date Code Title Description
AS Change of ownership

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH

Free format text: FORMER OWNER(S): MERCK PATENT GMBH

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180425